Oxford Therapeutics London
The GLP-1 Legacy
Life After Ozempic, Wegovy and Mounjaro
Over the past few years, medications such as Ozempic, Wegovy and Mounjaro have transformed the treatment of obesity. Millions of people around the world have lost significant amounts of weight using these appetite-regulating injections. But an important question often receives far less attention.e.
What happens after the injections stop? For many people, the real challenge begins when the medication ends. Appetite gradually returns, old habits can reappear, and the risk of weight regain becomes a genuine concern. The GLP-1 Legacy was written to address this exact problem. Many people are concerned about weight regain after Ozempic or Mounjaro, particularly once appetite begins to return. The GLP-1 Legacy explores the behavioural and psychological factors that influence whether weight loss can be maintained long term.
Drawing on more than 15,000 hours of clinical work helping people change their relationship with food and weight, Martin and Marion Shirran explore the psychological and behavioural side of long-term weight maintenance after GLP-1 medications.
The foreword to The GLP-1 Legacy is written by Professor Jane Ogden, one of the United Kingdom’s leading health psychologists and a widely published author in the field of eating behaviour and weight management. Her work over several decades has helped shape the understanding of the psychological factors that influence eating, dieting and long-term weight control. Her contribution to the book provides an important scientific perspective on the behavioural challenges people often face after stopping GLP-1 medications.
Why this book matters. Weight loss injections can be an effective tool, but they do not automatically change the habits, triggers and emotional patterns that influenced eating behaviour in the first place. When medication stops, many people are left asking the same questions. The book explores the transition people experience when stopping GLP-1 medication, including how appetite changes and what practical strategies can help maintain progress.
What happens after stopping Ozempic, Wegovy or Mounjaro?
How do I keep the weight off?
What happens when my appetite returns?
How do I avoid slipping back into old patterns?
The GLP-1 Legacy explores the behavioural and psychological side of this transition and provides practical insights for maintaining progress once medication ends.
What readers will learn
• Why appetite and food cravings can return after GLP-1 medications
• the behavioural traps that often lead to weight regain
• practical strategies for maintaining weight loss long term
• how to navigate restaurants, alcohol and social eating
• how habits and identity influence long-term success
• ways to build a sustainable relationship with food
About the authors
Martin and Marion Shirran have spent more than two decades helping people change their relationship with food and weight. Their work combines behavioural psychology with practical techniques developed through thousands of hours of clinical experience working with individuals struggling with weight, eating behaviour and lifestyle change. Their previous books have been published internationally, including by Hay House New York, and their work has been featured in major media outlets. The GLP-1 Legacy brings together clinical experience, behavioural science and real-world insight to help readers navigate life after weight-loss medication.
The GLP-1 Legacy is the essential guide for navigating the emotional, physical and psychological challenges that follow GLP-1 treatment. As countless users are now learning, weight loss is only half the battle. Maintenance is where the real work begins.
Authors Martin and Marion Shirran have created an essential guide, a roadmap to help patients transition and navigate what comes after the medications stop. While the injections helped them lose the weight, we know it’s their mindset, habits, and strategy going forward that will ensure the weight loss achieved is permanent. The book is overflowing with proven, practical, real-world advice to help them maintain their transformation and thrive. The readers are not starting over; they are moving forward. Throughout the book, readers are additionally introduced to a group of individuals who are in the post-GLP phase and have successfully navigated the transition.
Award-Winning Programme
The GLP-1 Legacy from Oxford Therapeutics has already piqued the interest of healthcare professionals aware of the importance of ‘wraparound’ care for individuals transitioning from GLP-1 therapy. Many have been seeking a proven behaviour change, diet/exercise programme for their patients, to partner with their prescribing of GLP-1 receptor agonists. It is hoped that this book will fill the void.
Food and Drug Administration
In the United States, the Food and Drug Administration (FDA) has mandated that GLP-1 receptor agonist weight-loss medications be prescribed in conjunction with a behavioural change programme. The FDA’s approach aims to ensure that patients not only lose weight but also adopt healthier lifestyle habits, which is crucial for maintaining their weight loss in the long term. This regulatory stance underscores the necessity of a comprehensive treatment plan, as detailed on the pages of this website.
NICE
Similarly, the National Institute for Health and Care Excellence (NICE) in the United Kingdom advocates a multifaceted approach to weight management. NICE recommends that weight-loss medications be integrated into a comprehensive weight management programme. The guidance from NICE emphasises the importance of addressing obesity through a holistic and sustainable approach, aiming to deliver long-term health benefits and improved quality of life for patients. Marion Shirran, the co-founder of Oxford Therapeutics Ltd, is a NICE stakeholder and a member of the All-Party Parliamentary Group on Obesity.
Oxford Therapeutics
Martin and Marion Shirran, the founders of Oxford Therapeutics, developed an upgrade to traditional Cognitive Behaviour Therapy (CBT) approaches and techniques. It’s known as Tactile Cognitive Behaviour Therapy, or TCBT. “In a single moment, you have elevated CBT from being a completely passive therapy into a useful tactile alternative!” (Dr Theano Kalavana). Academics, including Professor Windy Dryden of Goldsmiths University, London, and the late Professor Philip Zimbardo of Stanford University, in San Francisco, have endorsed the therapy. Professor Zimbardo wrote the foreword to their recent book regarding TCBT, published by Hay House.
Contact us
You can contact Martin and Marion Shirranby email or telephone:
You can email us directly at mmshirran@gmail.com
Alternatively, you can call the office on +44 203 769 5692 or in Spain on +34 951 311 591
Media and TV/Film enquiries oxfordtherapeuticsltd@gmail.com
For all press enquiries, please contact: martinfshirran@gmail.com
Stakeholder in NICE – National Institute for Health and Care Excellence
Marion Shirran, as a director of Oxford Therapeutics Limited, is a registered Stakeholder in NICE – National Institute for Health and Care Excellence.
All-Party Parliamentary Group on Obesity
Marion is proud to be a member of the All-Party Parliamentary Group on Obesity.
Please visit the contact page for email or telephone details.
